ProCE Banner Activity

Optimizing Frontline Therapy for Mantle Cell Lymphoma: The Evolving Role of BTK Inhibitors

Clinical Thought

Read this commentary to learn about the evolving evidence to refine and personalize frontline treatment strategies for patients with MCL with BTK inhibitors to achieve optimal outcomes.

Released: January 24, 2025

Expiration: January 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Brad Kahl, MD

Professor of Medicine
Washington University in St Louis
Director Lymphoma Service
Siteman Cancer Center
St Louis, Missouri

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADCT, AstraZeneca, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Merck, Pfizer, Roche/Genentech.